TD Asset Management Inc. decreased its position in AveXis, Inc. (NASDAQ:AVXS) by 22.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,247 shares of the company’s stock after selling 5,987 shares during the period. TD Asset Management Inc. owned approximately 0.08% of AveXis worth $1,746,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of AVXS. Quantitative Systematic Strategies LLC bought a new stake in AveXis during the first quarter worth $201,000. Candriam Luxembourg S.C.A. bought a new stake in AveXis during the first quarter worth $1,901,000. Credit Suisse AG raised its stake in AveXis by 36.4% in the first quarter. Credit Suisse AG now owns 63,228 shares of the company’s stock worth $4,807,000 after buying an additional 16,876 shares in the last quarter. Swiss National Bank raised its stake in AveXis by 3.0% in the first quarter. Swiss National Bank now owns 27,400 shares of the company’s stock worth $2,083,000 after buying an additional 800 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in AveXis by 11.7% in the first quarter. Vanguard Group Inc. now owns 1,194,809 shares of the company’s stock worth $90,841,000 after buying an additional 124,750 shares in the last quarter. 91.85% of the stock is currently owned by institutional investors and hedge funds.
AveXis, Inc. (NASDAQ AVXS) opened at 98.66 on Friday. AveXis, Inc. has a 52 week low of $32.31 and a 52 week high of $99.45. The company’s 50 day moving average is $88.93 and its 200-day moving average is $76.39. The firm’s market cap is $3.15 billion.
AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by $1.10. During the same period last year, the company earned ($0.68) EPS. Equities analysts expect that AveXis, Inc. will post ($5.86) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This story was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://stocknewstimes.com/2017/08/25/td-asset-management-inc-sells-5987-shares-of-avexis-inc-avxs.html.
A number of analysts have recently weighed in on AVXS shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $108.00 price objective (up previously from $92.00) on shares of AveXis in a research report on Friday, August 11th. BMO Capital Markets reaffirmed an “outperform” rating and set a $95.00 price objective on shares of AveXis in a research report on Friday, June 16th. Morgan Stanley reaffirmed an “overweight” rating and set a $118.00 price objective on shares of AveXis in a research report on Wednesday, August 9th. William Blair started coverage on AveXis in a research report on Wednesday. They set an “outperform” rating and a $107.00 price objective on the stock. Finally, Citigroup Inc. set a $100.00 price objective on AveXis and gave the stock a “buy” rating in a research report on Thursday, June 15th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $102.83.
In related news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $81.88, for a total transaction of $145,746.40. Following the completion of the sale, the vice president now directly owns 1,780 shares of the company’s stock, valued at approximately $145,746.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last ninety days, insiders have sold 5,340 shares of company stock valued at $434,872. 18.60% of the stock is owned by insiders.
About AveXis
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis, Inc. (NASDAQ:AVXS).
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
